entertainment -WSS

entertainment

author：Wikipedia 2025-09-27 19:37:06 - browse：45262

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

A group of advisers to the Food and Drug Administration voted in favor of Alnylam Pharmaceuticals’ treatment for a debilitating heart disease Wednesday, but only after a day-long debate challenging whether the drug’s modest observed effects were actually meaningful for patients.

The group of independent experts voted 9-3 that the benefits of Alnylam’s drug, called patisiran, outweighed its risks for patients with ATTR-CM, a progressive disease that leads to fatal heart failure if left untreated. The FDA, which is not required to follow the advice of advisers, is expected to make a final decision on patisiran by Oct. 8.

“It’s like a light wind blowing in favor of patisiran over placebo,” said David Cella, a neurologist at the Northwestern University Feinberg School of Medicine who voted in favor of patisiran. David Moliterno, a cardiologist at the University of Kentucky, added that “the good news in this story is that while there may be a small benefit, it doesn’t look like there’s a signal for harm.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Children’s Hospital revives plan for pedestrian bridge

hotspot

WSS

Man with guns arrested near Obama home 'attempted to evade' Secret Service: Prosecutors

CDC advisory group OKs chikungunya vaccine

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

3 protesters arrested at Wimbledon after interrupting matches by throwing confetti on court

Search warrant issued in 1996 disappearance of Kristin Smart

Doctor of U.S. President Joe Biden says he is fit for duty

focus

entertainment

focus

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

5 shark bites reported on Long Island as officials deploy surveillance drones

Medicare proposal to cover medical devices draws a mixed reaction

City of Memphis, police chief oppose effort to delay lawsuit in Tyre Nichols case

Apple is now the first public company to be valued at $3 trillion

Medicare Advantage isn’t working — for anyone

The cancer drug shortage isn’t new — and neither are the solutions

Laying a path for careers in science

The cancer drug shortage isn’t new — and neither are the solutions

Elisabeth Bik tackles the widespread issue of research misconduct

focus

Ph.D. graduate surprised with gift registry: 'You deserve to be celebrated'

Princess Kate attends Wimbledon with Roger Federer: See the photos

Former New York Mayor de Blasio and wife announce separation, but not divorce

Pope Francis asks Church to identify 21st

Laying a path for careers in science

Former New York Mayor de Blasio and wife announce separation, but not divorce

focus

explore

hotspot

knowledge